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Table 1
Risk factors of Hemorrhagic cystitis
Risk factors
Hazard ration
(95% CI) P-value
Age (years) 1.07 (1.02 e 1.12) 0.004
Male Male vs female 2.78 (0.63 e 12.5) 0.177
Keratinocyte
growth factor
Yes vs No 0.23 (0.03 e 1.92) 0.175
Mismatched donor Mismatched donor
vs matched donor
1.05 (0.30 e 3.66) 0.943
T-cell depleted TCD vs CONV 0.57 (0.16 e 1.99) 0.379
Cord blood
allografts
Cord blood vs
PBSC
2.23 (0.56 e 8.91) 0.256
Total body
irradiation
Yes vs No 0.61 (0.16 e 2.30) 0.46
aGVHD 2-3 aGVHD 2-3 vs
aGVHD 0-1
3.51 (0.64 e 19.33) 0.149
3-log BKV rise in
the urine
Yes vs No 1.98 (0.48 e 8.09) 0.344
Ciproﬂoxacin use* Yes vs No 0.17 (0.02 e 1.32) 0.091
Pre-HSCT urine BKV
‡ 107 copies/mL
107 copies/mLvs
<107 copies/mL
8.60 (2.35 e 31.40) 0.001
Post-HSCT urine BKV
‡ 107 copies/mL
107 copies/mLvs
<107 copies/mL
8.08 (1.85 e 35.26) 0.005
CONV indicates: Umbilical cord stem cell allografts, unmodiﬁed bone
marrow, and peripheral blood
* Ciproﬂoxacin use: from day -14 HSCT until day 14 post-HSCT
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Background: Hemorrhagic cystitis (HC) is a frequent
complication after HSCT and can signiﬁcantly affect the
patient's quality of life. BK virus (BKV), chemotherapy, irra-
diation, and graft versus host disease (GVHD) have been
associated with the pathogenesis of HC. To investigate the
relationship of HC and BKV, we prospectively evaluated
patient's BKV pre-HSCT serology and BKV in the urine, and
the association between BKV viruria and HC.
Methods: From April 2010 through October 2011, we
prospectively followed 98 adult HSCT patients. The patients
were monitored for BKV in the urine by quantitive poly-
merase chain reaction (Q-PCR) every 2 weeks from start of
conditioning until 15 weeks post-HSCT. Pre-HSCT BKV IgG
titers were measured by ELISA. All tests were performed by
Viracor-IBT Laboratories. BKV viruria was deﬁned as: 1
Q-PCR assay of >500 copies/mL; PEAK: 3-log increase in
BKV Q-PCR from pre-HSCT Q-PCR. A chart review was per-
formed to determine the development of HC. HC was graded
according to Bedi et al and was considered signiﬁcant if 
grade 2. Ciproﬂoxacin use was included from day -14
through day +14 post-transplant. Competing regression was
performed using clinical characteristics and urine BKV PCRs
to identify risk factors for development of HC.
Results: The median age of the patients was 52 years (range
20-73), 60% were male, 49% of patients underwent myeloa-
blative conditioning, 50% received T-cell depleted, and 21%
cord blood grafts. Acute grade 2-3 GVHD was diagnosed in
32% of patients and 31% had received Keratinocyte growth
factor (KGF) pretransplant. All patients (100%) were BKV IgG
positive pretransplant. By day 0, the cumulative incidence
(CI) of BKV viruria was 22%. By day+30, the CI was 50% and it
remained stable thereafter for the duration of the study. The
CI rates for BKV were similar among different stem cell
sources. Ten patients (10%) patients developed HC at
a median 40 days post transplant (range 0-146) and 7/10
(70%) patients with HC had BKV (2 with concomitant
adenovirus). Risk factors for HC were older age (P ¼ .004),
and BK viruria 107 copies/mL either pre- (P ¼ .001) or post-
HSCT (P ¼ .005). One of 30 patients (3%) who received KGF
developed HC and 9 of 68 patients (13%) who did not receive
KGF developed HC (P ¼ .175). One of 35 patients (3%) who
received ciproﬂoxacin developed HC and 9 of 63 patients
(14%) who did not receive ciproﬂoxacin developed HC
(P ¼ .091). During the study period, 36 patients died and 8
patients had autopsies performed. One of the 8 patients was
found to have BKV nephropathy at autopsy.
Conclusions: 1) In this study, the incidence of BK viruria was
not signiﬁcantly different among various stem cell sources.
2) High level BK viruria (107 copies/mL) and older age were
signiﬁcant predictors of HC. 3) While BK viruria was frequent(50%) during the study period, the rate of HC was low (10%)
suggesting additional co-factors in the pathogenesis of HC.376
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The Impact of Comorbidity and Performance Status in
Patients Undergoing Myeloablative Transplant Most diseases
treated by hematopoietic stem cell transplant (HSCT) occur
in individuals greater than 45 years of age. With the aging
population and the advent of new transplant regimens, the
incidence of comorbidities in the transplant patient pop-
ulation is increasing. Intensive chemotherapy causes
increased non-relapse mortality in this population. The
primary objective of this study is to determine if an associ-
ation exists between non-relapse mortality and calculated
comorbidity index (CMI) and Karnofsky performance (KPS)
scores in patients undergoing myeloablative preparative
regimens for HSCT. Secondary objectives were to assess the
impact of insurance on overall survival, speciﬁcally with high
CMI cases. We conducted a cross-sectional chart review of
HSCT patients at the Oklahoma tertiary referral hospital.
Eligible patients included adults ages 18-99 who received
amyeloablative allogeneic HSCT between 2007 and 2011. The
age range in our population ranged from 18-59. Data was
